Claims

1. Use of antibody to PD-1 in combination with at least one chemotherapeutic agent for treating a malignant neoplasm.

2. The use according to claim 1, wherein the antibody to PD-1 is administered at a dose of 0.5-10 mg/kg of body weight or at a dose of 100-400 mg.

3. The use according to claim 1, wherein the antibody to PD-1 is administered at a dose of 1 mg/kg or 3 mg/kg of body weight.

4. The use according to claim 1, wherein the antibody to PD-1 is administered every 2 weeks, or every 3 weeks, or every 4 weeks.

5. The use according to claim 1, wherein the antibody to PD-1 is administered at a dose of 1 mg/kg of body weight every 2 weeks
or at a dose of 3 mg/kg of body weight every 3 weeks.

6. The use according to claim 1, wherein the antibody to PD-1 is prolgolimab.

7. The use according to claim 1, wherein the chemotherapeutic agent is selected from the group comprising taxane, a platinum agent.

8. The use according to claim 1, wherein the chemotherapeutic agent is administered every 2 weeks, or every 3 weeks, or every 4 weeks.

9. The use according to claim 7, wherein taxane is selected from paclitaxel, docetaxel.

10. The use according to claim 9, wherein paclitaxel is administered at a dose of 135-175 mg/m^2.

11. The use according to claim 9, wherein paclitaxel is administered at a dose of 135 or 175 mg/m^2.

12. The use according to claim 7, wherein the platinum agent is selected from carboplatin, cisplatin.

13. The use according to claim 12, wherein cisplatin is administered at a dose of 50-100 mg/m^2.

14. The use according to claim 12, wherein cisplatin is administered at a dose of 50 mg/m^2.

15. The use according to claim 12, wherein carboplatin is administered at a dose of AUC 5-7.

16. The use according to claim 12, wherein carboplatin is administered at a dose of AUC 5.

17. The use according to claim 1, further being in combination with antibody to VEGF.

18. The use according to claim 17, wherein the antibody to VEGF is administered every 2 weeks, or every 3 weeks, or every 4 weeks.

19. The use according to claim 17, wherein the antibody to VEGF is bevacizumab.

20. The use according to claim 19, wherein bevacizumab is administered at a dose of 15 mg/kg of body weight.

21. Use of antibody to PD-1 in combination with paclitaxel and carboplatin or cisplatin for treating a malignant neoplasm.

22. The use according to claim 21, wherein the antibody to PD-1 at a dose of 1 mg/kg of body weight is administered every 2 weeks or every 3 weeks, paclitaxel at a dose of 175 mg/m^2 and carboplatin at a dose of AUC 5 are administered every 3 weeks; or

wherein the antibody to PD-1 at a dose of 3 mg/kg of body weight is administered every 2 weeks or every 3 weeks, paclitaxel at a dose of 175 mg/m^2 and carboplatin at a dose of AUC 5 are administered every 3 weeks; or

wherein the antibody to PD-1 at a dose of 1 mg/kg of body weight is administered every 2 weeks or every 3 weeks, paclitaxel at a dose of 175 mg/m^2 and cisplatin at a dose of 50 mg/m^2 are administered every 3 weeks; or

wherein the antibody to PD-1 at a dose of 3 mg/kg of body weight is administered every 2 weeks or every 3 weeks, paclitaxel at a dose of 175 mg/m^2 and cisplatin at a dose of 50 mg/m^2 are administered every 3 weeks.

23. The use according to claim 21, wherein the antibody to PD-1 is prolgolimab.

24. Use of antibody to PD-1 in combination with bevacizumab, paclitaxel, carboplatin or cisplatin for treating a malignant neoplasm.

25. The use according to claim 24, wherein the antibody to PD-1 at a dose of 1 mg/kg of body weight and bevacizumab at a dose of 15 mg/kg of body weight are administered every 2 weeks or every 3 weeks, paclitaxel at a dose of 175 mg/m^2 and carboplatin at a dose of AUC 5 are administered every 3 weeks; or

wherein the antibody to PD-1 at a dose of 3 mg/kg of body weight and bevacizumab at a dose of 15 mg/kg of body weight are administered every 2 weeks or every 3 weeks, paclitaxel at a dose of 175 mg/m^2 and carboplatin at a dose of AUC 5 are administered every 3 weeks; or

wherein the antibody to PD-1 at a dose of 1 mg/kg of body weight and bevacizumab at a dose of 15 mg/kg of body weight are administered every 2 weeks or every 3 weeks, paclitaxel at a dose of 175 mg/m^2 and cisplatin at a dose of 50 mg/m^2 are administered every 3 weeks; or

wherein the antibody to PD-1 at a dose of 3 mg/kg of body weight and bevacizumab at a dose of 15 mg/kg of body weight are administered every 2 weeks or every 3 weeks, paclitaxel at a dose of 175 mg/m^2 and cisplatin at a dose of 50 mg/m^2 are administered every 3 weeks.

26. The use according to claim 24, wherein the antibody to PD-1 is prolgolimab.

27. The use according to any of claims 1-26, wherein the malignant neoplasm is selected from the group comprising melanoma, including inoperable/metastatic melanoma, early stages of melanoma before and after definitive treatment; lung cancer, non-small cell lung cancer (NSCLC), including inoperable/metastatic non-small cell lung cancer, non-squamous cell non-small cell lung cancer, squamous cell lung cancer, small cell lung cancer, including inoperable/metastatic small cell lung cancer, early stage lung cancer before and after definitive treatment; cervical cancer, including metastatic cervical cancer, recurrent cervical cancer, progressive cervical cancer, persistent cervical cancer, early stages of cervical cancer before and after definitive treatment, head and neck cancers, including head and neck squamous cell carcinoma, Hodgkin's lymphoma, gastrointestinal cancer, metastatic esophageal squamous cell carcinoma, bladder cancer, including metastatic urothelial carcinoma, kidney cancer, endometrial cancer, including metastatic endometrial cancer, early stages of endometrial cancer before and after definitive treatment, breast cancer, including metastatic breast cancer, early stages of endometrial cancer before and after definitive treatment, liver cancer, including metastatic or inoperable liver cancer, early stages of liver cancer before and after definitive treatment, inoperable or metastatic solid tumor, including inoperable or metastatic solid tumor with evidence of microsatellite instability.

28. An antibody to PD-1 in combination with at least one chemotherapeutic agent for use in the manufacture of a medicament for treating a malignant neoplasm .

29. The antibody to PD-1 in combination with at least one chemotherapeutic agent for use according to claim 28, wherein the antibody to PD-1 is at a dose of 0.5-10 mg/kg of body weight or at a dose of 100-400 mg.

30. The antibody to PD-1 in combination with at least one chemotherapeutic agent for use according to claim 28, wherein the antibody to PD-1 is at a dose of 1 mg/kg or 3 mg/kg of body weight.

31. The antibody to PD-1 in combination with at least one chemotherapeutic agent for use according to claim 28, wherein the antibody to PD-1 is every 2 weeks, or every 3 weeks, or every 4 weeks.

32. The antibody to PD-1 in combination with at least one chemotherapeutic agent for use according to claim 28, wherein the antibody to PD-1 is at a dose of 1 mg/kg of body weight every 2 weeks or

at a dose of 3 mg/kg of body weight every 3 weeks.

33. The antibody to PD-1 in combination with at least one chemotherapeutic agent for use according to claim 28, wherein the antibody to PD-1 is prolgolimab.

34. The antibody to PD-1 in combination with at least one chemotherapeutic agent for use according to claim 28, wherein the chemotherapeutic agent is selected from the group comprising taxane, a platinum agent.

35. The antibody to PD-1 in combination with at least one chemotherapeutic agent for use according to claim 34, wherein taxane is selected from paclitaxel, docetaxel.

36. The antibody to PD-1 in combination with at least one chemotherapeutic agent for use according to claim 35, wherein paclitaxel is at a dose of 135-175 mg/m^2.

37. The antibody to PD-1 in combination with at least one chemotherapeutic agent for use according to claim 35, wherein paclitaxel is at a dose of 135 or 175 mg/m^2.

38. The antibody to PD-1 in combination with at least one chemotherapeutic agent for use according to claim 35, wherein the platinum agent is selected from carboplatin, cisplatin.

39. The antibody to PD-1 in combination with at least one chemotherapeutic agent for use according to claim 38, wherein cisplatin is at a dose of 50-100 mg/m^2.

40. The antibody to PD-1 in combination with at least one chemotherapeutic agent for use according to claim 389, wherein cisplatin is at a dose of 50 mg/m^2.

41. The antibody to PD-1 in combination with at least one chemotherapeutic agent for use according to claim 38, wherein carboplatin is at a dose of AUC 5-7.

42. The antibody to PD-1 in combination with at least one chemotherapeutic agent for use according to claim 38, wherein carboplatin is at a dose of AUC 5.

43. The antibody to PD-1 in combination with at least one chemotherapeutic agent for use according to claim 28, further comprising antibody to VEGF.

44. The antibody to PD-1 in combination with at least one chemotherapeutic agent for use according to claim 43, wherein the antibody to VEGF is bevacizumab.

45. The antibody to PD-1 in combination with at least one chemotherapeutic agent for use according to claim 44, wherein bevacizumab is at a dose of 15 mg/kg of body weight.

46. The antibody to PD-1 in combination with at least one chemotherapeutic agent for use according to any of claims 28-45, wherein the malignant neoplasm is selected from the group comprising melanoma, including inoperable/metastatic melanoma, early stages of melanoma before and after definitive treatment; lung cancer, non-small cell lung cancer (NSCLC), including inoperable/metastatic non-small cell lung cancer, non-squamous cell non-small cell lung cancer, squamous cell lung cancer, small cell lung cancer, including inoperable/metastatic small cell lung cancer, early stage lung cancer before and after definitive treatment; cervical cancer, including metastatic cervical cancer, recurrent cervical cancer, progressive cervical cancer, persistent cervical cancer, early stages of cervical cancer before and after definitive treatment, head and neck cancers, including head and neck squamous cell carcinoma, Hodgkin's lymphoma, gastrointestinal

cancer, metastatic esophageal squamous cell carcinoma, bladder cancer, including metastatic urothelial carcinoma, kidney cancer, endometrial cancer, including metastatic endometrial cancer, early stages of endometrial cancer before and after definitive treatment, breast cancer, including metastatic breast cancer, early stages of endometrial cancer before and after definitive treatment, liver cancer, including metastatic or inoperable liver cancer, early stages of liver cancer before and after definitive treatment, inoperable or metastatic solid tumor, including inoperable or metastatic solid tumor with evidence of microsatellite instability.

47. An antibody to PD-1 in combination with paclitaxel and carboplatin or cisplatin for use in the manufacture of a medicament for treating a malignant neoplasm .

48. The antibody to PD-1 in combination with paclitaxel and carboplatin or cisplatin for use according to claim 47, wherein the antibody to PD-1 is prolgolimab.

49. The antibody to PD-1 in combination with paclitaxel and carboplatin or cisplatin for use according to any of claims 47-48, wherein the malignant neoplasm is selected from the group comprising melanoma, including inoperable/metastatic melanoma, early stages of melanoma before and after definitive treatment; lung cancer, non-small cell lung cancer (NSCLC), including inoperable/metastatic non-small cell lung cancer, non-squamous cell non-small cell lung cancer, squamous cell lung cancer, small cell lung cancer, including inoperable/metastatic small cell lung cancer, early stage lung cancer before and after definitive treatment; cervical cancer, including metastatic cervical cancer, recurrent cervical cancer, progressive cervical cancer, persistent cervical cancer, early stages of cervical cancer before and after definitive treatment, head and neck cancers, including head and neck squamous cell carcinoma, Hodgkin's lymphoma, gastrointestinal cancer, metastatic esophageal squamous cell carcinoma, bladder cancer, including metastatic urothelial carcinoma, kidney cancer, endometrial cancer, including metastatic endometrial cancer, early stages of endometrial cancer before and after definitive treatment, breast cancer, including metastatic breast cancer, early stages of endometrial cancer before and after definitive treatment, liver cancer, including metastatic or inoperable liver cancer, early stages of liver cancer before and after definitive treatment, inoperable or metastatic solid tumor, including inoperable or metastatic solid tumor with evidence of microsatellite instability.

50. An antibody to PD-1 in combination with bevacizumab, paclitaxel, carboplatin or cisplatin for use in the manufacture of a medicament for treating a malignant neoplasm.

51. The antibody to PD-1 in combination with bevacizumab, paclitaxel, carboplatin or cisplatin for use according to claim 50, wherein the antibody to PD-1 is prolgolimab.

52. The antibody to PD-1 in combination with bevacizumab, paclitaxel, carboplatin or cisplatin for use according to any of claims 50-51, wherein the malignant neoplasm is selected from the group comprising melanoma, including inoperable/metastatic melanoma, early stages of

melanoma before and after definitive treatment; lung cancer, non-small cell lung cancer (NSCLC), including inoperable/metastatic non-small cell lung cancer, non-squamous cell non-small cell lung cancer, squamous cell lung cancer, small cell lung cancer, including inoperable/metastatic small cell lung cancer, early stage lung cancer before and after definitive treatment; cervical cancer, including metastatic cervical cancer, recurrent cervical cancer, progressive cervical cancer, persistent cervical cancer, early stages of cervical cancer before and after definitive treatment, head and neck cancers, including head and neck squamous cell carcinoma, Hodgkin's lymphoma, gastrointestinal cancer, metastatic esophageal squamous cell carcinoma, bladder cancer, including metastatic urothelial carcinoma, kidney cancer, endometrial cancer, including metastatic endometrial cancer, early stages of endometrial cancer before and after definitive treatment, breast cancer, including metastatic breast cancer, early stages of endometrial cancer before and after definitive treatment, liver cancer, including metastatic or inoperable liver cancer, early stages of liver cancer before and after definitive treatment, inoperable or metastatic solid tumor, including inoperable or metastatic solid tumor with evidence of microsatellite instability.